Oslo, Norway, 25 February 2025 - PCI Biotech (OSE: PCIB) invites to a webcast
presentation of the company's full-year 2024 interim report on Thursday 27
February 2025, 08:30am - 09:00am CET (local time).
The presentation will be held as a live webcast available through
www.pcibiotech.com. The presentation will be held in Norwegian. There will be a
Q&A session at the end of the presentation and it will be possible to post
written questions through the webcast console.
The interim report and presentation will be made available on www.newsweb.no and
on the company's webpage, www.pcibiotech.com, from 07.00am CET the same day.
For further information, please contact:
Ronny Skuggedal, CEO / CFO
Email: rs@pcibiotech.no
Mobile: +47 9400 5757
About PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on developing and
commercialising new technologies and novel therapies through its photochemical
technology platform originating from world-leading research at the Oslo
University Hospital. The technology platform is under development in two
different areas. (1) Photochemical lysis (PCL), inducing selective light-
triggered cell lysis, which may enhance yield and purity in viral vector
manufacturing. (2) Photochemical internalisation (PCI), inducing light-triggered
endosomal release, which may unlock the potential of a wide array of modalities.
For further information, please visit: www.pcibiotech.com
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379
Oslo
Forward-looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
PCI Biotech disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.